(HealthDay)—The 2014 recommendations for the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer are unchanged from 2013, according to an article published online Jan. 20 ...
Please provide your email address to receive an email when new articles are posted on . Venous thromboembolism is common in people with cancer, and has been reported in 4% to 20% of these patients.
For patients presenting with symptoms of venous thromboembolism, accurate diagnosis and treatment are essential. However, diagnosis and treatment alone are inadequate for hospitalized patients who are ...
The earliest published study on this topic was a retrospective case–control study by Northup and associates [8] focusing on 113 inpatients with cirrhosis who had newly diagnosed VTE during hospital ...
Stakeholders concurred that the occurrence of VTE events is a significant public health concern. According to Ralph J. Riello III, PharmD, “It is a problem often that hospitals do not know that they ...
Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT). Circulating tumor ...
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) The systematic review included 35 publications on ...
Twelve recommendations were agreed on by the panel from Johns Hopkins All Children's Hospital in St. Petersburg, FL. HealthDay News — Recommendations for anticoagulant prophylaxis for pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results